Interpharm Holdings Stock Performance
| IPAH Stock | USD 0 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Interpharm Holdings are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Interpharm Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Interpharm Holdings is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
Last Split Factor 1:5 | Last Split Date 1997-11-19 |
1 | CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDXs Path to Consolidated Financial Reporting - ... | 10/31/2025 |
Interpharm | Build AI portfolio with Interpharm Stock |
Interpharm Holdings Relative Risk vs. Return Landscape
If you would invest 0.41 in Interpharm Holdings on September 28, 2025 and sell it today you would earn a total of 0.00 from holding Interpharm Holdings or generate 0.0% return on investment over 90 days. Interpharm Holdings is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Interpharm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Interpharm Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Interpharm Holdings' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Interpharm Holdings, and traders can use it to determine the average amount a Interpharm Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IPAH |
Based on monthly moving average Interpharm Holdings is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Interpharm Holdings by adding Interpharm Holdings to a well-diversified portfolio.
Interpharm Holdings Fundamentals Growth
Interpharm Stock prices reflect investors' perceptions of the future prospects and financial health of Interpharm Holdings, and Interpharm Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Interpharm Stock performance.
| Return On Equity | -1.17 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 2.07 M | ||||
| Price To Sales | 0.03 X | ||||
| Revenue | 75.59 M | ||||
| Gross Profit | 12 M | ||||
| EBITDA | (16.57 M) | ||||
| Net Income | (14.06 M) | ||||
| Cash And Equivalents | 41 K | ||||
| Total Debt | 12.06 M | ||||
| Debt To Equity | 3.43 % | ||||
| Current Ratio | 0.62 X | ||||
| Book Value Per Share | (0.08) X | ||||
| Cash Flow From Operations | (14.11 M) | ||||
| Earnings Per Share | (0.09) X | ||||
| Market Capitalization | 2.07 M | ||||
| Total Asset | 74.37 M | ||||
| Working Capital | (16.64 M) | ||||
| Current Asset | 27.38 M | ||||
| Current Liabilities | 44.01 M | ||||
About Interpharm Holdings Performance
By evaluating Interpharm Holdings' fundamental ratios, stakeholders can gain valuable insights into Interpharm Holdings' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Interpharm Holdings has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Interpharm Holdings has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 105.37 | 110.64 | |
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.28) | (0.27) | |
| Return On Assets | (0.22) | (0.21) | |
| Return On Equity | (1.42) | (1.34) |
Things to note about Interpharm Holdings performance evaluation
Checking the ongoing alerts about Interpharm Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Interpharm Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Interpharm Holdings generated a negative expected return over the last 90 days | |
| Interpharm Holdings has some characteristics of a very speculative penny stock | |
| Interpharm Holdings currently holds 12.06 M in liabilities with Debt to Equity (D/E) ratio of 3.43, implying the company greatly relies on financing operations through barrowing. Interpharm Holdings has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Interpharm Holdings' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 75.59 M. Net Loss for the year was (14.06 M) with profit before overhead, payroll, taxes, and interest of 12 M. | |
| Interpharm Holdings currently holds about 41 K in cash with (14.11 M) of positive cash flow from operations. | |
| Interpharm Holdings has a poor financial position based on the latest SEC disclosures |
- Analyzing Interpharm Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Interpharm Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Interpharm Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Interpharm Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Interpharm Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Interpharm Holdings' stock. These opinions can provide insight into Interpharm Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Interpharm Stock analysis
When running Interpharm Holdings' price analysis, check to measure Interpharm Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpharm Holdings is operating at the current time. Most of Interpharm Holdings' value examination focuses on studying past and present price action to predict the probability of Interpharm Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Interpharm Holdings' price. Additionally, you may evaluate how the addition of Interpharm Holdings to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |